Research and Markets: The Competitor Analysis: Coagulation Factors Report Reveals - the Market Size of Coagulation Factor Products Exceeded US$ 7.5 Bln in 2008

DUBLIN--(Business Wire)--
Research and
Markets(http://www.researchandmarkets.com/research/a73724/competitor_analysi)
has announced the addition of the "Competitor Analysis: Coagulation Factors"
report to their offering.

The present Competitive Intelligence Report about Coagulation Factors provides a
competitor evaluation in the field of plasma-derived and recombinant coagulation
factors for topical or systemic administration to treat hereditary or acquired
coagulation disorders as of October 2009. Purchase of the downloadable pdf
report includes a 6-month online access to the data of the report and any
updates since the publication date. Credentials to access the database will be
sent by e-mail and allow online work with the project data to print or export an
individual report.

The market size of recombinant and plasma-derived coagulation factor products
exceeded US$ 7.5 bln in 2008, the majority (US$ 5.5 bln) generated by
recombinant proteins. Replacement of plasma-derived coagulation factors by
marketed recombinant molecules is ongoing and will further increase by new
recombinant coagulation factors in development. In light of ongoing expiration
of substance patents, about 40 new recombinant coagulation factor projects are
in the pipeline indicating a changing marketplace over the next decade. New
players are competing and will challenge established manufacturers and marketers
of coagulation factor products.

Apart from recombinant products, plasma-derived coagulation factors still play a
considerable role, albeit bovine derived products are considerably being
challenged by human recombinant and plasma-derived products. Coagulation factors
not only are being used for systemic treatment of hereditary coagulation factor
deficiencies, but also for topical or systemic treatment of bleedings.

The report includes a compilation of current active projects in research and
development of topical and systemic coagulation factors obtained by purification
of human plasma or by recombinant DNA technology. In addition, the report lists
company-specific R&D pipelines of coagulation factors. Competitor projects are
listed in a tabular format providing information on:

* Drug Codes,
* Target / Mechanism of Action,
* Class of Compound,
* Company,
* Product Category,
* Indication,
* R&D Stage and
* additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

* Coagulation Factor VIII
* Coagulation Factor IX
* Coagulation Factor VII
* Von Willebrand Factor (vWF)
* Fibrinogen
* Coagulation Factors V and XI
* Coagulation Factor X
* Coagulation Factor XIII
* Topical Fibrinogen and Thrombin Products
* Topical Thrombin Products
* Prothrombin Complex Concentrates
* Corporate Coagulation Factor Product and R&D Pipelines
* About La Merie

Some of the Companies Mentioned in this Report:-

Corporate Coagulation Factor Product and R&D Pipelines:

* Abraxis Biosciences
* Amsterdam Molecular Therapeutics
* Angiotech
* Apitope
* Biovitrum
* Catalyst Biosciences
* China Biologic Products
* Crucell
* CSL
* Ethicon (J&J)
* Genzyme
* Green Cross
* Jerini
* Kaketsuken
* Kamada
* Kedrion
* King Pharmaceuticals
* LFB
* Lipoxen
* Maxygen
* Nycomed
* Octapharma
* Oxford Biomedica
* Pharming
* ProFibrix
* Sinobiomed
* SK Chemicals
* Talecris Biotherapeutics
* Thrombotargets
* VIRxSYS
* Wyeth
* Zymogenetics

For more information visit
http://www.researchandmarkets.com/research/a73724/competitor_analysi

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009